The Top 5 Biosimilars Articles for the Week of May 27

May 31, 2019

The Center for Biosimilars® recaps the top news for the week of May 27, 2019.

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of May 27.

Number 5: New bipartisan legislation has been introduced to promote biosimilar education.

Number 4: The Senate Committee on Health, Education, Labor, and Pensions released draft legislation aimed at lowering the cost of healthcare in the United States.

Number 3: A new Federal Trade Commission report found that fewer drug patent settlements include provisions that are likely to be anticompetitive.

Number 2: UnitedHealthcare announced that it will prefer the use of brand-name pegfilgrastim, Neulasta, over biosimilar options.

Number 1: Officials in British Columbia announced that many patients currently taking reference biologics will be switched to biosimilars within 6 months.

Finally, last week, our e-newsletter asked how important you think factors like on-body injection or reduced administration of growth factors are to biosimilar uptake.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.